These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11570091)

  • 1. Once-daily therapy--results after one year.
    TreatmentUpdate; 2001; 12(12):4-5. PubMed ID: 11570091
    [No Abstract]   [Full Text] [Related]  

  • 2. Another take on when to start and how to succeed.
    Friedland GH
    AIDS Clin Care; 2001 Sep; 13(9):82. PubMed ID: 11547600
    [No Abstract]   [Full Text] [Related]  

  • 3. When to start?
    Bartlett J; Cohn D
    AIDS Clin Care; 1999 May; 11(5):38, 43. PubMed ID: 11367103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HIV-infection: modern antiretroviral therapy].
    Rockstroh JK; Spengler U
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1921-4. PubMed ID: 15372371
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Top stories of 2008. Antiretroviral rollout--successes and challenges.
    Friedland GH
    AIDS Clin Care; 2009 Jan; 21(1):5. PubMed ID: 19219959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV: it's beginning to look like a chronic disease.
    del Rio C
    AIDS Clin Care; 2001 Sep; 13(9):82-3. PubMed ID: 11547601
    [No Abstract]   [Full Text] [Related]  

  • 8. Adding two new drug classes improves outcome in salvage therapy.
    Havlir D
    AIDS Clin Care; 2001 Oct; 13(10):99. PubMed ID: 11590928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).
    Pujari S; Patel A; Joshi SR; Gangakhedkar R; Kumarasamy N; Gupta SB;
    J Assoc Physicians India; 2008 May; 56():339-48, 353-71. PubMed ID: 18700643
    [No Abstract]   [Full Text] [Related]  

  • 11. [Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():58-60. PubMed ID: 15373051
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Approval of a new nucleoside. Component of complete once daily regimen].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-HIV therapy update.
    Proj Inf Perspect; 2001 Mar; (32):4-6. PubMed ID: 11682776
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
    De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
    Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV agents. Five-year results from an NNRTI-based regimen.
    TreatmentUpdate; 2005; 17(1):6. PubMed ID: 17225317
    [No Abstract]   [Full Text] [Related]  

  • 19. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.